title: [Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Multiple Metastatic Breast Cancer Patients].
abstract: We evaluated the clinical significance of indoleamine 2,3-dioxygenase(IDO)during fulvestrant therapyfor multiple metastatic breast cancer patients. IDO activitycan be measured using the tryptophan(Trp)/kynurenine(Kyn)ratio. Trp and Kyn were measured using high-performance liquid chromatography(HPLC). The serum Trp/Kyn level in patients with multiple metastatic breast cancer was lower than in patients without metastases. IDO activityincreased after breast cancer metastases developed. IDO activitywas correlated with the number of metastatic lesions during toremifene and fulvestrant therapy. These results suggested that measurement of the Trp/Kyn ratio is useful to evaluate immunological metastatic status during endocrine therapy.
authors.affiliation: Division of Breast and Endocrine Surgery, Dept. of Surgery, Nihon University School of Medicine.
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sakurai
authors.forename: Shigeru
authors.initials: S
authors.lastname: Fujisaki
authors.forename: Keita
authors.initials: K
authors.lastname: Adachi
authors.forename: Shuhei
authors.initials: S
authors.lastname: Suzuki
authors.forename: Yuki
authors.initials: Y
authors.lastname: Masuo
authors.forename: Saki
authors.initials: S
authors.lastname: Nagashima
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Hara
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Hirano
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Enomoto
authors.forename: Ryouichi
authors.initials: R
authors.lastname: Tomita
authors.forename: Kenji
authors.initials: K
authors.lastname: Gonda
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology / Q000601:surgery; D018450:Disease Progression; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000378:metabolism*; D009362:Neoplasm Metastasis; D012008:Recurrence
chemical_list: D018931:Antineoplastic Agents, Hormonal; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D000077267:Fulvestrant; D004958:Estradiol